Previous 10 | Next 10 |
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the position of Chief Financial Officer (CFO) for personal reasons and moving into an advisory r...
For Q2 , ( ATRC -6.4% ) reported worldwide revenue of $40.8M (-30.7% Y/Y), beating consensus by $4.73M, as U.S. and International revenue dropped 28.6% and 39% respectively. More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Stocks on the move, ...
Image source: The Motley Fool. AtriCure Inc (NASDAQ: ATRC) Q2 2020 Earnings Call Jul 28, 2020 , 4:30 p.m. ET Operator Continue reading
AtriCure, Inc. (ATRC) Q2 2020 Earnings Conference Call July 28, 2020 4:30 P.M. ET Company Participants Lynn Lewis - Gilmartin Group Mike Carrel - President and Chief Executive Officer Andy Wade - Chief Financial Officer Conference Call Participants Suraj Kalia - Oppenheimer...
AtriCure (NASDAQ: ATRC ) : Q2 Non-GAAP EPS of -$0.38 beats by $0.16 ; GAAP EPS of -$0.20 beats by $0.37 . More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Worldwide revenue of $40.8 million – a decrease of 30.7% year over year U.S. revenue of $33.7 million – a decrease of 28.6% year over year International revenue of $7.1 million – a decrease of 39.0% year over year AtriCure, Inc. ( Nasdaq: ATRC ), a lead...
Quick Take Acutus Medical ( AFIB ) has filed to raise $75 million in an IPO of its common stock, according to an S-1 registration statement . The firm designs and sells various catheter-based ablation tools to treat cardiac arrhythmias. AFIB is in early commercialization stage for its i...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2020 financial results on Tuesday, July 28, 2020. AtriCure will host a conference call at...
Protalix Reports Positive Topline Results for Phase III Data Protalix BioTherapeutics Inc. ( PLX ) announced positive topline data from Phase III BRIDGE clinical trial of its lead drug candidate PRX-102. This Phase III study was an open label, single arm switch-over 12 month long study a...
AtriCure (NASDAQ: ATRC ) prices underwritten offering of 3,977,273 common shares at $44.00 per share for gross proceeds of $175M. More news on: AtriCure, Inc., Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval from the National Medical Products A...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2024 financial results on Tuesday, Ju...